Publications by authors named "Jo Ishizawa"

Claim this Profile
P
Protocol for isolation of lipid droplets and mitochondria from acute myeloid leukemia cells for lipidomic analysis.
Ran Zhao, Liang Zhang, Shuxin Dong, Kazuharu Kamachi, Saurabh Kumar Gupta, Jo Ishizawa

STAR Protoc· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cladribine, high-dose cytarabine, plus gemtuzumab ozogamicin (CLAG-GO) as frontline intensive therapy for fit patients with core-binding factor acute myeloid leukemia.
Roberta S Azevedo, Julie Braish, Georgina Gener-Ricos, Guilin Tang, Koji Sasaki, Jo Ishizawa

Leuk Lymphoma· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Outcome of 3q26.2/MECOM rearrangements in chronic myeloid leukemia.
Hiroki Akiyama, Hagop Kantarjian, Elias Jabbour, Ghayas Issa, Fadi G Haddad, Jo Ishizawa

Int J Hematol· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mitochondrial regulation of GPX4 inhibition-mediated ferroptosis in acute myeloid leukemia.
Hiroki Akiyama, Ran Zhao, Lauren B Ostermann, Ziyi Li, Matthew Tcheng, Jo Ishizawa

Leukemia· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction: Mitochondrial regulation of GPX4 inhibition-mediated ferroptosis in acute myeloid leukemia.
Hiroki Akiyama, Ran Zhao, Lauren B Ostermann, Ziyi Li, Matthew Tcheng, Jo Ishizawa

Leukemia· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Oral decitabine plus cedazuridine and venetoclax in patients with higher-risk myelodysplastic syndromes or chronic myelomonocytic leukaemia: a single-centre, phase 1/2 study.
Alex Bataller, Guillermo Montalban-Bravo, Alexandre Bazinet, Yesid Alvarado, Kelly Chien, Jo Ishizawa

Lancet Haematol· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Enhanced reactivation disrupts transcriptional program and overcomes venetoclax resistance in acute myeloid leukemias.
Yuki Nishida, Jo Ishizawa, Edward Ayoub, Rafael Heinz Montoya, Lauren B Ostermann

Sci Adv· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mitophagy Promotes Resistance to BH3 Mimetics in Acute Myeloid Leukemia.
Christina Glytsou, Xufeng Chen, Emmanouil Zacharioudakis, Wafa Al-Santli, Hua Zhou, Jo Ishizawa

Cancer Discov· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Phase I study of Milademetan (DS3032b) in combination with low dose cytarabine with or without venetoclax in acute myeloid leukemia: Clinical safety, efficacy, and correlative analysis.
Jayastu Senapati, Muharrem Muftuoglu, Jo Ishizawa, Hussein A Abbas, Sanam Loghavi

Blood Cancer J· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Epithelial SOX9 drives progression and metastases of gastric adenocarcinoma by promoting immunosuppressive tumour microenvironment.
Yibo Fan, Yuan Li, Xiaodan Yao, Jiangkang Jin, Ailing Scott, Jo Ishizawa

Gut· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Molecular Mechanisms of Ferroptosis and Updates of Ferroptosis Studies in Cancers and Leukemia.
Hiroki Akiyama, Bing Z Carter, Michael Andreeff, Jo Ishizawa

Cells· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction: Discovery and clinical introduction of first-in-class imipridone ONC201.
Joshua E Allen, C Leah B Kline, Varun V Prabhu, Jessica Wagner, Jo Ishizawa

Oncotarget· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Inhibition of translation initiation factor eIF4a inactivates heat shock factor 1 (HSF1) and exerts anti-leukemia activity in AML.
Yuki Nishida, Ran Zhao, Lauren E Heese, Hiroki Akiyama, Shreya Patel, Jo Ishizawa

Leukemia· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Imipridone ONC212 activates orphan G protein-coupled receptor GPR132 and integrated stress response in acute myeloid leukemia.
Takenobu Nii, Varun V Prabhu, Vivian Ruvolo, Neel Madhukar, Ran Zhao, Jo Ishizawa

Leukemia· December 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
BETP degradation simultaneously targets acute myelogenous leukemia stem cells and the microenvironment.
Sujan Piya, Hong Mu, Seemana Bhattacharya, Philip L Lorenzi, R Eric Davis, Jo Ishizawa

J Clin Invest· May 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mitochondrial ClpP-Mediated Proteolysis Induces Selective Cancer Cell Lethality.
Jo Ishizawa, Sarah F Zarabi, R Eric Davis, Ondrej Halgas, Takenobu Nii

Cancer Cell· May 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Combinatorial targeting of XPO1 and FLT3 exerts synergistic anti-leukemia effects through induction of differentiation and apoptosis in -mutated acute myeloid leukemias: from concept to clinical trial.
Weiguo Zhang, Charlie Ly, Jo Ishizawa, Hong Mu, Vivian Ruvolo

Haematologica· October 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targeting of BMI-1 expression by the novel small molecule PTC596 in mantle cell lymphoma.
Aya Maeda, Yuki Nishida, Marla Weetall, Liangxian Cao, Arthur Branstrom, Jo Ishizawa

Oncotarget· June 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Predictive Gene Signatures Determine Tumor Sensitivity to MDM2 Inhibition.
Jo Ishizawa, Kenji Nakamaru, Takahiko Seki, Koichi Tazaki, Kensuke Kojima

Cancer Res· May 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Imipridone ONC201 Induces Apoptosis and Overcomes Chemotherapy Resistance by Up-Regulation of Bim in Multiple Myeloma.
Yong-Sheng Tu, Jin He, Huan Liu, Hans C Lee, Hua Wang, Jo Ishizawa

Neoplasia· October 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
FZR1 loss increases sensitivity to DNA damage and consequently promotes murine and human B-cell acute leukemia.
Jo Ishizawa, Eiji Sugihara, Shinji Kuninaka, Kaoru Mogushi, Kensuke Kojima

Blood· April 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bone Marrow Adipocytes Facilitate Fatty Acid Oxidation Activating AMPK and a Transcriptional Network Supporting Survival of Acute Monocytic Leukemia Cells.
Yoko Tabe, Shinichi Yamamoto, Kaori Saitoh, Kazumasa Sekihara, Norikazu Monma, Jo Ishizawa

Cancer Res· March 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery and clinical introduction of first-in-class imipridone ONC201.
Joshua E Allen, C Leah B Kline, Varun V Prabhu, Jessica Wagner, Jo Ishizawa

Oncotarget· November 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacological activation of wild-type p53 in the therapy of leukemia.
Kensuke Kojima, Jo Ishizawa, Michael Andreeff

Exp Hematol· September 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
ATF4 induction through an atypical integrated stress response to ONC201 triggers p53-independent apoptosis in hematological malignancies.
Jo Ishizawa, Kensuke Kojima, Dhruv Chachad, Peter Ruvolo, Vivian Ruvolo

Sci Signal· February 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis